The sheer enormity of the people who could potentially benefit from these drugs has really led to a significant level of foot dragging among public and private payers, and its not because they dont believe that these pharmaceuticals actually work in terms of improving patient outcomes, he told Straight Arrow
Your provider can adjust your plan if a different medication is a better fit

Detailed week-by-week protocol This expanded chart includes practical guidance for each phase: Phase 1: Initiation (Weeks 1-4) Dose: 2 mg once weekly What to expect: Reduced appetite (often noticed within days) Possible mild nausea (usually transient) Some reduction in food cravings Minimal weight loss during this phase Tips: Establish your injection routine Track symptoms in a journal Note your baseline weight and measurements Don't expect dramatic results yet Side effects at this phase: Usually mild if present Most common: slight nausea, mild fullness If severe: contact your provider before escalating Phase 2: First escalation (Weeks 5-8) Dose: 4 mg once weekly What to expect: More noticeable appetite suppression Possible increase in nausea (typically resolves in 1-2 weeks) Beginning of measurable weight loss Some may notice improved energy Tips: Eat smaller, more frequent meals Avoid high-fat and fried foods Stay well-hydrated (minimum 64 oz water daily) If nausea is severe, hold at 2 mg for 2 more weeks Side effects at this phase: GI symptoms often peak here Nausea, occasional vomiting, bloating possible Most symptoms improve by week 7-8 Phase 3: Building dose (Weeks 9-12) Dose: 6 mg once weekly What to expect: Significant appetite reduction Noticeable weight loss (often 5-10% by week 12) Body adapting to medication Side effects often improving from week 5-8 Tips: Continue hydration focus Prioritize protein intake to preserve muscle Consider light exercise if energy permits Monitor for any new symptoms Note: Some protocols skip 6 mg and go directly from 4 mg to 8 mg

GLP-1 Medications We Prescribe Semaglutide Semaglutide is a GLP-1 receptor agonist that helps regulate appetite and blood sugar
Incidence of GLP-1 receptor agonist use by women of reproductive age attending general practices in Australia, 20112022: A retrospective open cohort study